Zomedica Pharmaceuticals Corp (ZOM)

$0.61 0.02 (2.84%)

20:00 EDT ZOM Stock Quote Delayed 30 Minutes

Zomedica Is Still Working Out How to Sell Truforma. Can Investors Afford to Wait?

By Dana Blankenhorn, InvestorPlace Contributor Jul 20, 2021

Zomedica came public too soon, but it does have enough cash to see a finish line. The question is, can ZOM stock investors afford to wait?

Ignore Zomedica’s Recent Struggles. The Road Ahead Remains Bright.

Speculative Investors Are Crazy Not to Buy Zomedica at Its Current Prices

Wait for Zomedica to Give Up More of its Meme Stock Gains

Volume:

Previous Close -

Market Cap 594.35M

PE Ratio -7.63

EPS -0.08

Volume (Avg. Vol.) 13.18M

Day's Range 0.61 - 0.64

52-Week Range 0.06 - 2.91

Dividend & Yield N/A (N/A)

ZOM Stock Predictions, Articles, and Zomedica Pharmaceuticals Corp News

From InvestorPlace
From the Web

Zomedica Stock Still Has a Rocky Few Months Left Ahead of It

By Alex Sirois Jul 14, 2021

ZOM stock is rife with massive potential. But it's the same potential that has gone unfulfilled for the past few months.

7 Penny Stocks You Can Pick Up for Less Than a Dollar

By Muslim Farooque Jul 13, 2021

These penny stocks are trading at cheap valuations, but they also have the potential to make major waves this year.

A Little Patience Could Go a Long Way For ZOM Stock

By Chris Markoch Jul 12, 2021

ZOM stock is trading below $1 as investors are in a holding pattern as they wait for the company to report earnings in August.

Zomedica Is Way Undervalued Here as Its Gear Is Catching On

By Will Ashworth, InvestorPlace Contributor Jun 28, 2021

InvestorPlace’s Mark Hake estimates Zomedica is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy. Here’s why I agree.

Radio Silence May Indicate a Problem for Zomedica Stock

By Dana Blankenhorn, InvestorPlace Contributor Jun 24, 2021

Zomedica is due to report results for the current quarter on Aug. 11. Until then, investors have nothing with which to weigh ZOM stock.

7 Penny Stocks That Could Be the Next Big Thing

By Steve Booyens Jun 23, 2021

Diversify your portfolio with 7 high-return penny stocks that could be the next big thing based on facts instead of fantasy.

Zomedica Stock Has More Headwinds Than the Rest of the Pet Industry

By Josh Enomoto, InvestorPlace Contributor Jun 23, 2021

On paper, ZOM stock seems like a no-brainer due to enthusiasm for pet ownership but dig deeper and you’ll find less promising data.

7 Penny Stocks Under a Penny That Are Worth a Look

By Faisal Humayun Jun 17, 2021

These penny stocks under $1 have the potential to trend higher. They are the stocks of businesses with decent fundamentals.

Zomedica Is Good Value and May Be Worth $1.36 — Or More

By Mark R. Hake, CFA Jun 15, 2021

Zomedica is good value looks like it will go on the acquisition warpath. ZOM stock is worth between $1.11 and $1.61, or $1.36 on average, providing an average 20% ROI over 2 years.

Zomedica Is Surprisingly Cheap Even as Commercialization Commences

By Louis Navellier and the InvestorPlace Research Staff Jun 14, 2021

ZOM stock has spiked sharply this year, but a recent price pullback could signal an ideal entry point for pet care market investors.

7 Penny Stocks To Watch Before They Pop Due to Reddit Users

By Faizan Farooque Jun 11, 2021

Penny stocks are not usually on lists of must-buy stocks, but that does not mean these companies cannot explode in the coming weeks.

Zomedica’s Risks Are Too Big to Ignore

By Stavros Georgiadis, CFA, InvestorPlace Contributor Jun 2, 2021

You may like ZOM stock as a pet lover, but not for its fundamentals, nor its valuation until it starts having credible financial results.

Zomedica’s High Share Count Creates Challenges for ZOM Stock

By Tom Kerr, InvestorPlace Contributor Jun 2, 2021

Zomedica has promising growth potential, but its high share count makes ZOM stock a risky investment. Here's what investors should know.

Zomedica Stock Will Be Worth The Risk After Another Drop

By Thomas Niel Jun 1, 2021

Another pullback in ZOM stock will put this long-term speculative play's odds in your favor if its Truforma product catches on.

Right-Priced Zomedica Could Be an Investor’s Best Friend

By Louis Navellier and the InvestorPlace Research Staff Jun 1, 2021

The skeptics might misinterpret the company's first-quarter revenue data, but a deeper dive should uncover reasons to hold on to ZOM stock.

Bets on Zomedica’s In-Office Vet Test Could Payoff or Bust by Year-End

By Dana Blankenhorn, InvestorPlace Contributor May 27, 2021

Zomedica's Truforma machine has entered the vet equipment market, which is consolidating rapidly. That means results on whether this can work should come quickly for ZOM stock investors.

Is Zomedica Making a Change For the Better?

By Chris Markoch May 26, 2021

ZOM stock trades below $1 as investors wait to see if recent changes to the company's business model along with potential acquisitions can be a catalyst for revenue.